News | April 05, 2021
Zydus seeks DCGI approval for the use of Pegylated Interferon alpha-2b in treating COVID-19
PegIFN in COVID19 has several add-on advantages compared to other anti-viral agents
PegIFN in COVID19 has several add-on advantages compared to other anti-viral agents
Integration of various regulatory agencies with a single-window system and putting in place a transparent, stable, predictable and easy to navigate interface.
Pharma industry is ready to embrace technology platforms with a keen focus on automation in manufacturing and digital health investment.
Building upon the momentum gained by pharma sector during the pandemic, Indian Pharmaceutical Alliance is leaving no stone unturned to create a faster road to recovery.
While top industry leaders are optimistic about the growth, they expect the special incentives and regulatory streamlining from the government’s side
The company posted net profit of Rs.7.61 crores for the period ended December 31, 2019.
The company posted net profit of Rs.203.38 crores for the period ended December 31, 2019.
The company posted net loss of Rs. 661.16 crores for the period ended December 31, 2019.
The company has posted net profit of Rs.19.8 crores for the period ended December 31, 2020 as against net loss of Rs. 569.7 crores for the period ended December 31, 2019.
The company has reported total income of Rs.14759 crores during the 9 months period ended December 31, 2020.
Subscribe To Our Newsletter & Stay Updated
